<DOC>
	<DOC>NCT02413372</DOC>
	<brief_summary>The purpose of this study is to determine whether BMS-986036 is effective in the treatment of subjects with Non-alcoholic Steatohepatitis (NASH).</brief_summary>
	<brief_title>A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Male or female between 21 and 75 years old Body Mass Index (BMI) of 25 or more Chronic Liver disease other than NASH Uncontrolled diabetes Any major surgery within 6 weeks of screening Unable to selfadminister under the skin injections Any bone trauma, fracture or bone surgery within 8 weeks of screening</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>First Line Therapy</keyword>
	<keyword>NASH</keyword>
</DOC>